ArticleFrontiers in endocrinology2025
Development of a nomogram for predicting renal survival in patients with biopsy-proven diabetic nephropathy.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prediction models for progression from diabetic kidney disease to end-stage renal disease: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Risk Stratification for Diabetic Kidney Disease Progression in Predicting All-Cause and Cardiovascular Mortality in Type 2 Diabetes: A National Cohort Study From NHANES 1999-2018.Journal of diabetes research · 2026Article
- Development and validation of a predictive nomogram for differentiating diabetic nephropathy from non-diabetic nephropathy in patients with T2DM: a multicenter study.Frontiers in nutrition · 2025Article
- High glucose-induced PLCG1 histone acetylation to promote ferroptosis by LAMP2A/HSPA8 in a diabetic nephropathy model.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy (DN) has emerged as the leading cause of chronic kidney disease, with a significant proportion of DN patients progressing to end-stage kidney disease (ESKD), profoundly affecting their quality of life. Currently, no single clinical marker reliably predicts the likelihood and timing of progression to ESKD in DN patients. This study aims to develop a non-invasive predictive model to evaluate the risk and timing of ESKD onset in this population. Methods: This study retrospectively analyzed data from 140 biopsy-confirmed DN patients. Key predictive variables were identified using multivariate Cox regression analysis, and a visual predictive nomogram was developed. The model was subsequently evaluated for its predictive performance. Results: Of the 140 DN patients, 81 progressed to ESKD. Multivariate analysis identified estimated glomerular filtration rate, common logarithm of albumin-creatinine ratio, cystatin C, hemoglobin, and fibrinogen as independent predictors of progression to ESKD. Based on these significant factors, a nomogram was constructed. The area under the time-dependent receiver operating characteristic curve at 1, 2, 3, and 5 years were 0.898 (95% CI: 0.839-0.958), 0.889 (95% CI: 0.818-0.959), 0.876 (95% CI: 0.785-0.968), and 0.893 (95% CI: 0.796-0.990), respectively. Calibration curves demonstrated strong concordance between predicted and observed outcomes, while decision curve analysis indicated substantial net clinical benefit for practical application. Conclusions: This study developed a predictive model to assess the risk and timing of ESKD progression in DN patients. As a quantitative tool, this model enables clinicians to estimate the 5-year risk of ESKD, facilitating timely interventions to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.